BACKGROUND: Mutational loss of tumor suppressor phosphatase and tensin homologue deleted on chromosome ten (PTEN) is associated with malignant progression in many cancers, including colorectal cancer (CRC). PTEN is involved in negatively regulating the phosphatidylinositol 3-kinase/AKT oncogenic signaling pathway and has been implicated in the metastatic colonization process. Few in vivo models are available to study CRC metastasis. The purpose of this study was to determine the effect of restoring PTEN activity on metastases in an orthotopic murine model. METHODS: Green fluorescent protein labeled TENN, a highly metastatic human colon cancer cell line with mutational loss of PTEN gene and TENN clones (with restoration of PTEN gene) tumors were orthotopically implanted onto the colons of BALB/c nude mice and allowed to develop primary and metastatic tumors. Seven weeks post-implantation, mice were euthanized and organs extracted for examination. RESULTS: Both TENN and TENN clone cell lines demonstrated 100% primary invasion. However, compared with the parental TENN cells, which demonstrated 62% metastases to both lungs and liver, TENN clone cells showed an approximately 50% reduction in metastasis, with only 31.6% liver metastasis and no metastasis to the lungs (P = 0.02). CONCLUSIONS: Our study shows that reactivation of PTEN tumor suppressor pathway leads to a 50% reduction in CRC metastasis without affecting primary tumor formation. Importantly, PTEN restoration also changed the organotropic homing from liver and lung metastasis to liver metastasis only. This in vivo study demonstrates that PTEN might act specifically as a metastasis suppressor and, thus, efforts to target the phosphatidylinositol 3-kinase/PTEN pathway are legitimate.
BACKGROUND: Mutational loss of tumor suppressor phosphatase and tensin homologue deleted on chromosome ten (PTEN) is associated with malignant progression in many cancers, including colorectal cancer (CRC). PTEN is involved in negatively regulating the phosphatidylinositol 3-kinase/AKT oncogenic signaling pathway and has been implicated in the metastatic colonization process. Few in vivo models are available to study CRC metastasis. The purpose of this study was to determine the effect of restoring PTEN activity on metastases in an orthotopic murine model. METHODS: Green fluorescent protein labeled TENN, a highly metastatic humancolon cancer cell line with mutational loss of PTEN gene and TENN clones (with restoration of PTEN gene) tumors were orthotopically implanted onto the colons of BALB/c nude mice and allowed to develop primary and metastatic tumors. Seven weeks post-implantation, mice were euthanized and organs extracted for examination. RESULTS: Both TENN and TENN clone cell lines demonstrated 100% primary invasion. However, compared with the parental TENN cells, which demonstrated 62% metastases to both lungs and liver, TENN clone cells showed an approximately 50% reduction in metastasis, with only 31.6% liver metastasis and no metastasis to the lungs (P = 0.02). CONCLUSIONS: Our study shows that reactivation of PTEN tumor suppressor pathway leads to a 50% reduction in CRC metastasis without affecting primary tumor formation. Importantly, PTEN restoration also changed the organotropic homing from liver and lung metastasis to liver metastasis only. This in vivo study demonstrates that PTEN might act specifically as a metastasis suppressor and, thus, efforts to target the phosphatidylinositol 3-kinase/PTEN pathway are legitimate.
Authors: D Williams Parsons; Tian-Li Wang; Yardena Samuels; Alberto Bardelli; Jordan M Cummins; Laura DeLong; Natalie Silliman; Janine Ptak; Steve Szabo; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Christoph Lengauer; Victor E Velculescu Journal: Nature Date: 2005-08-11 Impact factor: 49.962
Authors: B Vogelstein; E R Fearon; S R Hamilton; S E Kern; A C Preisinger; M Leppert; Y Nakamura; R White; A M Smits; J L Bos Journal: N Engl J Med Date: 1988-09-01 Impact factor: 91.245
Authors: Ashwani Rajput; Alan P Koterba; Jeffrey I Kreisberg; Jason M Foster; James K V Willson; Michael G Brattain Journal: Cancer Res Date: 2007-01-15 Impact factor: 12.701
Authors: Piotr G Rychahou; JungHee Kang; Pat Gulhati; Hung Q Doan; L Andy Chen; Shu-Yuan Xiao; Dai H Chung; B Mark Evers Journal: Proc Natl Acad Sci U S A Date: 2008-12-15 Impact factor: 11.205
Authors: K Podsypanina; L H Ellenson; A Nemes; J Gu; M Tamura; K M Yamada; C Cordon-Cardo; G Catoretti; P E Fisher; R Parsons Journal: Proc Natl Acad Sci U S A Date: 1999-02-16 Impact factor: 11.205
Authors: Ashwani Rajput; Ivan Dominguez San Martin; Rebecca Rose; Alexander Beko; Charles Levea; Elizabeth Sharratt; Richard Mazurchuk; Robert M Hoffman; Michael G Brattain; Jing Wang Journal: J Surg Res Date: 2007-10-24 Impact factor: 2.192
Authors: Jing Wang; Karen Kuropatwinski; Jennie Hauser; Michael R Rossi; Yunfei Zhou; Alexis Conway; Julie L C Kan; Neil W Gibson; James K V Willson; John K Cowell; Michael G Brattain Journal: Mol Cancer Ther Date: 2007-03 Impact factor: 6.261
Authors: Michele Milella; Italia Falcone; Fabiana Conciatori; Ursula Cesta Incani; Anais Del Curatolo; Nicola Inzerilli; Carmen M A Nuzzo; Vanja Vaccaro; Sabrina Vari; Francesco Cognetti; Ludovica Ciuffreda Journal: Front Oncol Date: 2015-02-16 Impact factor: 6.244
Authors: Lin Zheng; Yuqin Zhang; Yan Liu; Min Zhou; Yanxia Lu; Li Yuan; Chao Zhang; Min Hong; Shuang Wang; Xuenong Li Journal: J Transl Med Date: 2015-08-04 Impact factor: 5.531
Authors: Erik D Hedrick; Ekta Agarwal; Premila D Leiphrakpam; Katie L Haferbier; Michael G Brattain; Sanjib Chowdhury Journal: J Mol Signal Date: 2013-10-01
Authors: Eduardo Silva-Pavez; Paulina Villar; César Trigo; Esteban Caamaño; Ignacio Niechi; Pablo Pérez; Juan P Muñoz; Francisco Aguayo; Verónica A Burzio; Manuel Varas-Godoy; Ariel F Castro; María I Colombo; Julio C Tapia Journal: Cell Death Dis Date: 2019-01-25 Impact factor: 8.469